Kato T, Nishimura H, Yamabe T, Terashima Y, Kasamatsu T, Hirabayashi K, Nishiya I, Yajima A, Takamizawa H, Tsutsui F
Dept. of Obstetrics and Gynecology, Kurume University, School of Medicine.
Gan To Kagaku Ryoho. 1988 Aug;15(8):2297-304.
A phase III study of carboplatin vs cisplatin in CAP regimen for ovarian cancer was conducted by a cooperative study group consisting of 22 institutions nationwide. The response rate for 23 cases allocated to carboplatin regimen group was 34.8% and 42.1% for 19 cases allocated to cisplatin regimen group. No significant difference was observed between these two regimens in response rates, and no significant differences were noted between the two regimens in each of the clinical toxicities and abnormalities in laboratory findings. Since the carboplatin regimen group did not require hydration, or the use diuretics or antiemetics, these results suggested that carboplatin is more useful in the treatment of ovarian cancer than cisplatin.
一个由全国22个机构组成的合作研究小组开展了一项关于卡铂与顺铂用于卵巢癌CAP方案治疗的III期研究。分配至卡铂方案组的23例患者的缓解率为34.8%，分配至顺铂方案组的19例患者的缓解率为42.1%。这两种方案在缓解率方面未观察到显著差异，并且在每种临床毒性和实验室检查异常方面，两种方案之间也未发现显著差异。由于卡铂方案组不需要水化、使用利尿剂或止吐药，这些结果表明卡铂在卵巢癌治疗中比顺铂更有用。
